RBC Capital Sticks to Their Buy Rating for ABN AMRO Group N.V. (0RDM)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Reingen covers the Financial sector, focusing on stocks such as UBS Group AG, BNP Paribas, and Deutsche Bank AG. According to TipRanks, Reingen has an average return of 18.4% and a 70.98% success rate on recommended stocks.
In addition to RBC Capital, ABN AMRO Group N.V. also received a Buy from UBS's Johan Ekblom in a report issued on July 10. However, on the same day, Morgan Stanley maintained a Hold rating on ABN AMRO Group N.V. (LSE: 0RDM).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Jim Cramer Says Reports Of Apple Inc. (AAPL)'s 'Death' Are Overblown
We recently published . Apple Inc. (NASDAQ:AAPL) is one of the stocks Jim Cramer recently discussed. Giuseppe Costantino/ Apple Inc. (NASDAQ:AAPL)'s shares have reversed tack recently as the firm appears to have smoothed over its friction with the Trump administration. The firm announced a $100 billion additional investment in the US earlier this month, and the shares have gained 13.8% since then. Cramer discussed Apple Inc. (NASDAQ:AAPL)'s shares adding 30 dollars to their value in ten days: 'Well we've got a lot of exciting things that people are talking about. About the release perhaps of new AI powered products. Uh, smart home push, including robots. Life like version of Siri, well that would certainly be helpful. Smart speaker with display and home security camera. I don't know, home security is something that people want but the main thing here is that if we get robots and they're not from Musk, they're from Apple, I think we'd be very interested in that. While we acknowledge the potential of AAPL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
an hour ago
- Business Insider
QQQ ETF News, 8/20/2025
How is QQQ stock faring? The Invesco QQQ ETF has declined 0.79% over the past five days, but is up 13.2% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks' unique ETF analyst consensus, which is based on a weighted average of its holdings' analyst ratings, QQQ is a Moderate Buy. The Street's average price target of $638.41 for the QQQ ETF implies an upside potential of about 12.1%. Currently, QQQ's five holdings with the highest upside potential are Strategy (MSTR), Charter Communications (CHTR), Atlassian Corporation (TEAM), Trade Desk (TTD), and Lululemon Athletica (LULU). (PLTR), Tesla (TSLA), Intel (INTC), and Fastenal (FAST).
Yahoo
4 hours ago
- Yahoo
PTC Therapeutics CRL ‘expected,' focus moves to Sephience, says RBC Capital
PTC Therapeutics (PTCT) on Tuesday announced that they received a complete response letter for vatiquinone in Friedreich's ataxia, with the FDA stating that substantial evidence of efficacy was not demonstrated and that an additional adequate and well-controlled study would be needed, RBC Capital tells investors in a research note. The firm believes this was generally expected and already baked into the stock, and thinks the focus will hone in on the Sephience launch. RBC Capital, which has an Outperform rating and $63 price target on the stock, would buy shares. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on PTCT: Disclaimer & DisclosureReport an Issue PTC Therapeutics: Buy Rating Maintained Despite Vatiquinone Setback PTC Therapeutics price target lowered to $50 from $56 at TD Cowen PTC Therapeutics: Hold Rating Amid Regulatory Setbacks and Sephience Growth Potential PTC Therapeutics Receives FDA Complete Response Letter PTC Therapeutics receives Complete Response Letter for vatiquinone NDA Sign in to access your portfolio
